- Home
- GRND vs RCKT Comparison
GRND vs RCKT Comparison
Compare GRND & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRND | RCKT |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 340.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GRND | RCKT |
|---|---|---|
| Price | $13.41 | $3.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $22.75 | ★ $29.12 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $411,545,000.00 | N/A |
| Revenue This Year | $29.03 | N/A |
| Revenue Next Year | $21.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.97 | N/A |
| 52 Week Low | $11.73 | $2.19 |
| 52 Week High | $25.13 | $13.35 |
Technical Indicators
Market Signals| Indicator | GRND | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 53.27 |
| Support Level | $12.86 | $3.19 |
| Resistance Level | $14.24 | $3.60 |
| Average True Range (ATR) | 0.36 | 0.19 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 37.32 | 59.78 |
Price Performance
Historical ComparisonAbout GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.